PLX vs. NLCP

Last updated Jun 4, 2026

PLX (Protalix BioTherapeutics, Inc.) and NLCP (NewLake Capital Partners, Inc.) are both stocks. PLX operates in Biotechnology (Healthcare), while NLCP operates in REIT - Specialty (Real Estate). Over the past 3 years, PLX returned -3.92%/yr vs 18.10%/yr for NLCP. At a 0.13 correlation, their price movements are largely independent.

Performance

PLX vs. NLCP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Protalix BioTherapeutics, Inc. (PLX) and NewLake Capital Partners, Inc. (NLCP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PLX achieves a 8.89% return, which is significantly higher than NLCP's -4.15% return.

PLX

• 1D: -1.51%
• 1M: -7.98%
• YTD: 8.89%
• 6M: 13.95%
• 1Y: 22.50%
• 3Y*: -3.92%
• 5Y*: -1.74%
• 10Y*: -13.01%

NLCP

• 1D: -0.20%
• 1M: 3.49%
• YTD: -4.15%
• 6M: 26.03%
• 1Y: 13.17%
• 3Y*: 18.10%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PLX vs. NLCP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
PLX Protalix BioTherapeutics, Inc.	8.89%	-4.26%	5.62%	29.93%	64.72%	-37.93%
NLCP NewLake Capital Partners, Inc.	-4.15%	2.42%	19.43%	11.85%	-39.27%	-2.96%

Correlation

The correlation between PLX and NLCP is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.14
Correlation (3Y) Calculated over the trailing 3-year period	0.12
Correlation (All Time) Calculated using the full available price history since Aug 23, 2021	0.13

Fundamentals

Market Cap PLX : $162.78M NLCP : $311.51M
EPS PLX : $0.19 NLCP : $1.23
PE Ratio PLX : 10.34 NLCP : 12.06
PS Ratio PLX : 2.08 NLCP : 6.20
PB Ratio PLX : 1.72 NLCP : 0.81
Total Revenue (TTM) PLX : $76.38M NLCP : $50.17M
Gross Profit (TTM) PLX : $53.44M NLCP : $6.26M
EBITDA (TTM) PLX : $20.91M NLCP : $42.43M

Return for Risk

PLX vs. NLCP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PLX

PLX Risk / Return Rank: 53
PLX Sharpe Ratio Rank: 53
PLX Sortino Ratio Rank: 52
PLX Omega Ratio Rank: 52
PLX Calmar Ratio Rank: 54
PLX Martin Ratio Rank: 52

NLCP

NLCP Risk / Return Rank: 57
NLCP Sharpe Ratio Rank: 60
NLCP Sortino Ratio Rank: 55
NLCP Omega Ratio Rank: 53
NLCP Calmar Ratio Rank: 60
NLCP Martin Ratio Rank: 59

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PLX vs. NLCP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and NewLake Capital Partners, Inc. (NLCP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PLX	NLCP	Difference
Sharpe ratio Return per unit of total volatility	0.34	0.56	-0.22
Sortino ratio Return per unit of downside risk	0.92	1.05	-0.13
Omega ratio Gain probability vs. loss probability	1.12	1.12	0.00
Calmar ratio Return relative to maximum drawdown	0.57	0.89	-0.32
Martin ratio Return relative to average drawdown	1.07	1.84	-0.77
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PLX vs. NLCP - Sharpe Ratio Comparison

The current PLX Sharpe Ratio is 0.34, which is lower than the NLCP Sharpe Ratio of 0.56. The chart below compares the historical Sharpe Ratios of PLX and NLCP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	PLX	NLCP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.34	0.56	-0.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.03	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.16	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	-0.18	+0.11

Drawdowns

PLX vs. NLCP - Drawdown Comparison

The maximum PLX drawdown since its inception was -99.91%, which is greater than NLCP's maximum drawdown of -58.59%. Use the drawdown chart below to compare losses from any high point for PLX and NLCP.

Drawdown Indicators

	PLX	NLCP	Difference
Max Drawdown Largest peak-to-trough decline	-99.91%	-58.59%	-41.32%
Max Drawdown (1Y) Largest decline over 1 year	-39.68%	-14.78%	-24.90%
Max Drawdown (3Y) Largest decline over 3 years	-62.96%	-35.06%	-27.90%
Max Drawdown (5Y) Largest decline over 5 years	-73.21%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-94.37%	—	—
Current Drawdown Current decline from peak	-99.78%	-27.51%	-72.27%
Average Drawdown Average peak-to-trough decline	-93.66%	-33.75%	-59.91%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.01%	7.17%	+13.84%

Volatility

PLX vs. NLCP - Volatility Comparison

Protalix BioTherapeutics, Inc. (PLX) has a higher volatility of 13.87% compared to NewLake Capital Partners, Inc. (NLCP) at 8.87%. This indicates that PLX's price experiences larger fluctuations and is considered to be riskier than NLCP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PLX	NLCP	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.87%	8.87%	+5.00%
Volatility (6M) Calculated over the trailing 6-month period	44.36%	19.33%	+25.03%
Volatility (1Y) Calculated over the trailing 1-year period	66.69%	23.67%	+43.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	67.72%	29.95%	+37.77%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.33%	29.95%	+49.38%

Dividends

PLX vs. NLCP - Dividend Comparison

PLX has not paid dividends to shareholders, while NLCP's dividend yield for the trailing twelve months is around 11.61%.

Position	TTM	2025	2024	2023	2022	2021
NLCP NewLake Capital Partners, Inc.	11.61%	10.80%	9.71%	9.81%	8.99%	1.50%
PLX Protalix BioTherapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

PLX vs. NLCP - Profitability Comparison

The chart below illustrates the profitability comparison between Protalix BioTherapeutics, Inc. and NewLake Capital Partners, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a gross profit of 29.62M and revenue of 33.75M. Therefore, the gross margin over that period was 87.8%.

NLCP - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NewLake Capital Partners, Inc. reported a gross profit of 0.00 and revenue of 12.31M. Therefore, the gross margin over that period was 0.0%.

PLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported an operating income of 21.15M and revenue of 33.75M, resulting in an operating margin of 62.7%.

NLCP - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NewLake Capital Partners, Inc. reported an operating income of 6.01M and revenue of 12.31M, resulting in an operating margin of 48.9%.

PLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a net income of 18.32M and revenue of 33.75M, resulting in a net margin of 54.3%.

NLCP - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NewLake Capital Partners, Inc. reported a net income of 5.78M and revenue of 12.31M, resulting in a net margin of 46.9%.

Frequently Asked Questions

Can I hold both PLX and NLCP in my portfolio?

PLX and NLCP have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PLX or NLCP?

PLX has higher volatility (13.87%) compared to NLCP (8.87%). In terms of maximum drawdown, PLX dropped -99.91% vs NLCP's -58.59%.

Which has better risk-adjusted returns?

NLCP currently has the higher Sharpe Ratio (0.56 vs 0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.